ApollomicsAPLM
APLM
About: Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
Employees: 45
0
Funds holding %
of 7,363 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
0.93% less ownership
Funds ownership: 2.09% [Q3] → 1.17% (-0.93%) [Q4]
55% less funds holding
Funds holding: 11 [Q3] → 5 (-6) [Q4]
60% less capital invested
Capital invested by funds: $323K [Q3] → $129K (-$194K) [Q4]
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Research analyst outlook
We haven’t received any recent analyst ratings for APLM.
Financial journalist opinion
Neutral
GlobeNewsWire
2 months ago
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
FOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today the results from its Phase 3 bridging trial of uproleselan in China in patients with relapsed or refractory acute myeloid leukemia. The trial did not demonstrate favorable benefit for uproleselan.
Neutral
GlobeNewsWire
3 months ago
Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
FOSTER CITY, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that on December 10, 2024, it received a notification (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Rule 5550(a)(2) (the “Bid Price Requirement”), and Nasdaq has determined to continue the listing of the Company's Class A ordinary shares (“Class A Ordinary Shares”) on the Nasdaq Capital Market under the symbol “APLM.”
Neutral
GlobeNewsWire
6 months ago
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
FOSTER CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced Company management will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference taking place on September 9-11, 2024 virtually and in person at the Lotte New York Palace Hotel in New York, NY.
Neutral
GlobeNewsWire
6 months ago
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
FOSTER CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the first half of 2024 ended June 30, 2024, and highlighted updates for its pipeline.
Neutral
GlobeNewsWire
6 months ago
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
43% overall response rate: Six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial responses) confirmed by RECIST 1.1 out of 14 patients with solid tumors harboring MET gene fusions 43% overall response rate: Six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial responses) confirmed by RECIST 1.1 out of 14 patients with solid tumors harboring MET gene fusions
Neutral
GlobeNewsWire
7 months ago
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
FOSTER CITY, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today that it received written notification from The Nasdaq Stock Market LLC (“Nasdaq”) that it has granted the Company's request for a 180-day extension to regain compliance with the continued listing requirements for The Nasdaq Capital Market. As previously disclosed, Apollomics had received a notice from Nasdaq on January 16, 2024 that it is not in compliance with the Bid Price Requirement (as defined below), because the closing bid price of the Company's Ordinary Shares was below $1.00 per share for 30 consecutive business days.
Neutral
GlobeNewsWire
8 months ago
Apollomics Announces Updated Strategic Focus and Leadership Team Changes
Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need
Neutral
GlobeNewsWire
10 months ago
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
Apollomics' partner in China, Avistone, received approval from National Medical Products Administration of China to expand the use of vebreltinib to the treatment of gliomas with PTPRZ1-MET fusion gene
Neutral
GlobeNewsWire
11 months ago
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying MET-driver alterations, and effective for overcoming MET-amplification dependent resistance to EGFR therapies in EGFR-positive non-small cell lung cancer Preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying MET-driver alterations, and effective for overcoming MET-amplification dependent resistance to EGFR therapies in EGFR-positive non-small cell lung cancer
Neutral
Seeking Alpha
11 months ago
Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript
Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript
Charts implemented using Lightweight Charts™